Balance Sheet

Accounts Payables Accumulated Expenses Assets Buildings Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Current Assets Current Deferred Revenue Current Leases Current Taxes Dividends payables Finished Goods Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Income Statement

Others

Ratios

Zhengye Biotechnology Holding (ZYBT) Operating Leases (2025)

Zhengye Biotechnology Holding has reported Operating Leases over the past 1 years, most recently at $46104.6 for Q4 2025.

Quarterly Operating Leases changed N/A to $46104.6 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $46104.6 through Dec 2025, changed N/A year-over-year, with the annual reading at $47000.0 for FY2025, N/A changed from the prior year.
Operating Leases was $46104.6 for Q4 2025 at Zhengye Biotechnology Holding.
Over five years, Operating Leases peaked at $46104.6 in Q4 2025 and troughed at $46104.6 in Q4 2025.